HRX Innovation Challenge: Deadline is June 3, 2024

HRX Innovation Challenge: Deadline is June 3, 2024

Jennifer Silva

Director Pediatric Electrophysiology

Washington University SOM

Moderated Sessions

September 06, 2024 | 11:30 AM (EDT) - 12:15 AM (EDT)

About Jennifer N. Avari Silva, MD, FHRS

Jennifer Silva is Director of Pediatric Electrophysiology and a Professor of Pediatrics and Biomedical Engineering at Washington University School of Medicine/St. Louis Children’s Hospital, and serves as the Faculty Fellow in Entrepreneurship for Washington University SOM. She serves on committees within the Heart Rhythm Society (Chair, Women in Electrophysiology; VChair, Growth and Leadership Opportunity for Women in Electrophysiology; Production Team, HRX; Member, Membership Committee) Pediatric and Congenital Electrophysiology Society (Vice President of Finance), American College of Cardiology (with leadership roles on the Innovation Council, Industry Advisory Forum, Applied Health and Innovation Council) and serves on the NIH-SBIR study section for Cardiovascular Innovation. She is a Senior Member of the National Academy of Inventors and serves on the Editorial Boards of numerous journals including Circulation: Arrhythmia and ElectrophysiologyHeart Rhythm O2, and Cardiovascular Digital Health journals.

The scope of her research has been in innovation and emerging technologies with on developing and identifying clinical applications of new and emerging technologies within cardiac electrophysiology, particularly in the scope of wearable and advanced wearable technologies, including the extended realities.

Jennifer is the co-inventor and co-founder of SentiAR, Inc, a venture-backed software device spinout from Washington University which is developing the first mixed reality platform to display intraprocedural 3-dimensional holographic visualization of a patient’s cardiac anatomy with real time catheter locations with submission to the FDA in 2019.  In 2018, the company received a NIH-SBIR award for $2.2M, in 2021 closed a $5.1M Series A Round, and is currently closing a >$6M Series B. Most recently, she has co-founded a second company, Excera, Inc. which aims to improve outcomes for ultrasound-guided minimally invasive procedures. She has worked with several medical device companies including AliveCor, St Jude Medical/Abbott, Medtronic and Biosense Webster regarding development and implementation of novel technologies targeted to unmet clinical needs and development of regulatory pathways.


Honoraria/Speaking/Consulting Fee: Medtronic, Inc., SentiAR, Inc., Cardialen, Inc., Abbott Medical, Janssen Pharmaceuticals, AltaThera Pharmaceuticals, iRhythm Technologies
Ownership/Partnership/Principal: SentiAR, Inc., Excera, Inc.
Stocks – Privately Held: SentiAR, Inc.
Stock Options – Privately Held: Excera, Inc.